Elicio Therapeutics Inc stock is traded at $1.40, with a volume of 282,074. It is down -10.26% in the last 24 hours and down -25.53% over the past month. Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Previous Close:
$1.56
Open:
$1.58
24h Volume:
282,074
Relative Volume:
0.89
Market Cap:
$37.93M
Revenue:
-
Net Income/Loss:
-$40.19M
P/E Ratio:
-
EPS:
-$2.34
Net Cash Flow:
-$38.49M
1W Performance:
-16.67%
1M Performance:
-25.53%
6M Performance:
-86.60%
1Y Performance:
-84.56%
1-Day Range:
$0.00$0.00
1-Week Range:
$1.40$1.80
52-Week Range:
$1.40$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(857) 209-0050Address
451 D STREET, 5TH FLOOR, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS